financetom
Business
financetom
/
Business
/
Palantir Strengthens Army Partnership, Adds AI And Data Enhancements In $618.9 Million Contract
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Palantir Strengthens Army Partnership, Adds AI And Data Enhancements In $618.9 Million Contract
Dec 19, 2024 4:12 AM

Palantir Technologies Inc. ( PLTR ) shares are trading higher premarket on Thursday. On Wednesday, the company disclosed an extension of its partnership with the U.S. Army to continue delivering the Army Vantage capability for the “Army Data Platform.”

The agreement is valued at $400.7 million over four years, with a total potential ceiling of $618.9 million.

The new agreement aims to operationalize data across the entire Department of the Army, enabling broader integration of data and AI capabilities.

The program is set to expand, offering greater flexibility to support additional Army initiatives while enhancing interoperability and integration through advanced technology investments.

As of 2024, the Vantage program has supported over 100,000 users and achieved record-high usage.

The platform currently integrates more than 180 unique data sources, enabling seamless connectivity across the Army and Joint community.

Looking forward, the program will maintain its existing capabilities and infrastructure while expanding to serve mission owners across the entire Army enterprise.

Akash Jain, President, Palantir USG said, “Our continuous addition of new AI capabilities enables the Army’s own ability to develop applications and incorporate the benefits of effective data analysis across nearly every high-priority mission in the Army.”

Investors can gain exposure to the stock via Adaptiv Select ETF ( ADPV ) and  ProShares Big Data Refiners ETF ( DAT ) .

Price Action: PLTR shares are up 1.97% at $72.92 premarket at the last check Thursday.

Read Next:

Palantir’s Alex Karp Embraces ‘Cult’ Status, Complains About The Missing Perks As Stock Soars 350%

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kyverna Therapeutics Q1 Loss Narrows
Kyverna Therapeutics Q1 Loss Narrows
May 14, 2024
05:09 PM EDT, 05/14/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) reported a Q1 net loss late Tuesday of $1.12 per diluted share, compared with a loss of $12.10 per share a year earlier. A single analyst polled by Capital IQ expected a loss of $0.80. No revenue was reported for the quarter ended March 31, as expected for...
Thinkific Announces Substantial Issuer Bid
Thinkific Announces Substantial Issuer Bid
May 14, 2024
05:11 PM EDT, 05/14/2024 (MT Newswires) -- Thinkific Labs ( THNCF ). (THNC.TO) Tuesday announced the launch of a substantial issuer bid to purchase for cancellation up to $47.8 million of its subordinate voting shares at a price of $3.72 per Subordinate Voting Share. The Offer will not be conditional upon any minimum number of subordinate voting shares being tendered....
Unifor Affiliated CNTL Drivers Ratify New Collective Agreement
Unifor Affiliated CNTL Drivers Ratify New Collective Agreement
May 14, 2024
05:11 PM EDT, 05/14/2024 (MT Newswires) -- CN (CNR.TO) announced after hours Tuesday that the tentative agreement between CNTL, a CN subsidiary involved in first and last mile trucking container pickup and deliveries, and owner-operators affiliated with Unifor has been ratified. This four-year agreement covers 750 owner-operators under contract with CNTL in Canada until December 31, 2027. ...
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
May 14, 2024
Arcutis Biotherapeutics, Inc. ( ARQT ) reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights.  The Details: Arcutis Biotherapeutics ( ARQT ) reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved